<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261572</url>
  </required_header>
  <id_info>
    <org_study_id>3550-CL-0009</org_study_id>
    <nct_id>NCT01261572</nct_id>
  </id_info>
  <brief_title>Study to Find Maintenance Dose for Periodic Administration of ASP3550</brief_title>
  <official_title>Phase II Study of ASP3550 - A Maintenance-dose Finding Study for Periodic Dosage Regimen in Patients With Prostate Cancer -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in
      patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASP3550 is administered periodically to patients with prostate cancer. The primary efficacy
      variable is the effect of ASP3550 on the maintenance of serum testosterone suppression. In
      addition, the safety and pharmacokinetics of ASP3550 will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proportion of patients with serum testosterone ≤0.5 ng/mL over time</measure>
    <time_frame>Baseline and for one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum level of testosterone over time</measure>
    <time_frame>Baseline and for one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum level of Luteinizing Hormone (LH) over time</measure>
    <time_frame>Baseline and for one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum level of Follicle Stimulating Hormone (FSH) over time</measure>
    <time_frame>Baseline and for one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum level of Prostate Specific Antigen (PSA) over time</measure>
    <time_frame>Baseline and for one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the recurrence of serum PSA</measure>
    <time_frame>For one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluated by the incidence of Adverse Events (AEs), physical exam and results of lab tests</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP3350 high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP3350 low dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP3350</intervention_name>
    <description>periodic injection</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven prostate cancer (adenocarcinoma) of all stages

          -  A patient in whom endocrine treatment is indicated. Patients with rising serum PSA
             after having prostatectomy or radiotherapy performed with curative intention

          -  Serum testosterone level above 2.2 ng/mL

          -  An ECOG (Eastern Co-operative Oncology Group) P.S. (Performance Status) score of 0 to
             2

          -  Serum PSA level above 2 ng/mL

        Exclusion Criteria:

          -  Previous or present endocrine treatment for prostate cancer. However, patients who
             have undergone neoadjuvant/adjuvant endocrine therapy for a maximal duration of 6
             months and in whom prostatectomy or radiotherapy was terminated at least 6 months

          -  Treated with a 5α-reductase inhibitor

          -  A candidate for curative therapy, i.e., radical prostatectomy or radiotherapy within
             12 months

          -  Concurrent or a history of severe liver disease

          -  Abnormal ECG such as long QTc

          -  A patient receiving ASP3550 in past times

          -  Administered drug in another clinical study or a post-market clinical study in the 28
             days prior to the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shiku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Touhoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>July 8, 2013</last_update_submitted>
  <last_update_submitted_qc>July 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP3550</keyword>
  <keyword>Degarelix</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Prostatic neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

